Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bone Biologics CorpBBLG · Entity 8560 | Director | September 28, 2026 | September 30, 2026 |
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director | June 09, 2026 | June 11, 2026 |
| Opus Genetics, Inc.IRD · Entity 5892 | Chief Financial Officer | September 03, 2026 | September 08, 2026 |
| PURPLE BIOTECH LTD.PPBT · Entity 8457 | Director | March 18, 2026 | March 18, 2026 |
| Verastem, Inc.VSTM · Entity 5242 | Director | December 16, 2025 | December 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bone Biologics Corp
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2036-09-28 | Direct | 113,896 |
Reported balance
After 2026-09-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-28 · Grant · Acquired 113,896 · Balance 113,896 F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.28 · Expires 2035-06-04 | Direct | 10,483 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 10,483 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.38 · Expires 2034-09-17 | Direct | 5,119 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,119 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $25.44 · Expires 2034-01-08 | Direct | 2 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 2 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $25.44 · Expires 2034-01-08 | Direct | 1,335 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,335 F2: This option is fully exercisable as of the date of this report. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.
F2: This option is fully exercisable as of the date of this report.
HARVARD BIOSCIENCE INC
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,556 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 16,556 · Balance 27,556 F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2: Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person. F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
F2: Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.
F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Opus Genetics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 556,375 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Sale · Disposed 28,000 · Balance 556,375 F1: A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer. F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer.
F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
PURPLE BIOTECH LTD.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 3,062,500 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,062,500 F1: Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 56 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.146765625 per Ordinary Share and the option expires on December 29, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24,2026.The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2029.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,454,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
F2: Represents stock option to purchase 112,500 Ordinary Shares (equivalent to 56 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.146765625 per Ordinary Share and the option expires on December 29, 2026.
F3: Represents stock option to purchase 300,000 Ordinary Shares (equivalent to 150 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 274,997 Ordinary Shares are vested and exercisable, with the remaining options to purchase 25,003 Ordinary Shares vesting in equal quarterly installments until April 24,2026.The exercise price of this stock option is $0.059375 per Ordinary Share and the option expires on April 24, 2028.
F4: Represents stock option to purchase 2,650,000 Ordinary Shares (equivalent to 1,325 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 220,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 2,429,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2029.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.
Verastem, Inc.
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,678 |
Reported balance
After 2025-12-16 transaction · row 1
1 source rowRow 1 · 2025-12-16 · Sale · Disposed 283 · Balance 41,678 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2021 Filed Dec 17, 2021 21:02 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 301,500 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001104659-21-151112 · tm2135712-2_4seq1.xml · derivative · entry 3 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,500 Underlying: Common Stock · 301,500 shares Expires 2031-12-15 F3 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of December 15, 2021 (the "Option Grant Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Option Grant Date until the fourth anniversary of the Option Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:02 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 148,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151112 · tm2135712-2_4seq1.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,398 F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on the first anniversary of December 15, 2021 (the "RSU Grant Date") and as to an additional 6.25% of the RSUs at the end of each successive three-month period following the first anniversary of the RSU Grant Date until the fourth anniversary of the RSU Grant Date (with the number of RSUs vesting on each vesting date rounded down to the nearest whole RSU, except with respect to the final vesting date on which all remaining unvested RSUs shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| August 12, 2021 Filed Dec 17, 2021 21:02 UTC | Verastem, Inc. VSTM · Entity 5242 | Tax withholdingCommon Stock | 45,329 | $2.87 | $130,094.23 |
DisclosureSEC source: 0001104659-21-151112 · tm2135712-2_4seq1.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,898 F1 · balance_after: The total reflects the disposition of 45,329 shares sold by the Issuer to satisfy statutory withholding requirements upon vesting of restricted stock units and additional reductions of 74,981 shares previously retired and 18,760 shares previously sold, in each case by the Issuer, to satisfy statutory withholding requirements upon vesting of restricted stock units. The total also reflects 3,333 shares purchased under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 18:33 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 203,776 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0000904454-20-000832 · edgar.xml · derivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,776 Underlying: Common Stock · 203,776 shares Expires 2030-12-18 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of December 18, 2020 (the "Grant Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Grant Date until the fourth anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 18:33 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 67,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000832 · edgar.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,635 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2012 Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on the first anniversary of December 18, 2020 (the "Grant Date") and as to an additional 6.25% of the RSUs at the end of each successive three-month period following the first anniversary of the Grant Date until the fourth anniversary of the Grant Date (with the number of RSUs vesting on each vesting date rounded down to the nearest whole RSU, except with respect to the final vesting date on which all remaining unvested RSUs shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 16:01 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 290,210 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000568 · edgar.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,710 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Issuer's Amended and Restated 2012 Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of Common Stock. The restricted stock units vest 50% on December 31, 2020 and 50% on August 11, 2021, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 00:59 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-040698 · a4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,500 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Issuer's Amended and Restated 2012 Incentive Plan on March 27, 2020. Each restricted stock unit represents the contingent right to receive one share of Common Stock. The restricted stock units vest as to 100% of the shares on December 31, 2021, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on such vesting date. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 00:40 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001104659-19-073507 · a4.xml · derivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-12-13 F2 · derivative.exercise_date: The option vests as to 50% of the shares on the first anniversary of Grant Date and as to an additional 12.5% of the shares at the end of each successive three-month period following the first anniversary of the Grant Date, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 00:40 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001104659-19-073507 · a4.xml · derivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-12-13 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of December 13, 2019 (the "Grant Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Grant Date until the fourth anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| June 21, 2019 Filed Jun 26, 2019 01:49 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001104659-19-037504 · a4.xml · derivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-06-21 F2 · derivative.exercise_date: The option vests as to 50% of the shares on the first anniversary of the date of grant and as to an additional 12.5% of the shares at the end of each successive three-month period following the first anniversary of the date of grant, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| June 21, 2019 Filed Jun 26, 2019 01:49 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-037504 · a4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,000 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2012 Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 50% of the RSUs on the first anniversary of the date of grant and as to an additional 12.5% of the RSUs at the end of each successive three-month period following the first anniversary of the date of grant, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on such vesting date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:45 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000904454-19-000026 · edgar.xml · derivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-03 F2 · derivative.exercise_date: The option vests as to: (a) 40% of the shares upon the date on which the closing price per share of the common stock is at least $10.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, (b) 40% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $15.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, and (c) 20% of the shares shall vest upon the date on which the closing price per share of the common stock is at least $20.00 on at least 20 (whether or not consecutive) of the prior 30 trading days, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:45 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000904454-19-000026 · edgar.xml · derivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of January 1, 2019 (the "Commencement Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Commencement Date until the fourth anniversary of the Commencement Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| August 29, 2018 Filed Aug 30, 2018 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 8,889 | $5.77 | $51,289.53 |
DisclosureSEC source: 0001209191-18-048919 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,169 F1 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (e) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; and (f) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 20:50 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000904454-18-000543 · edgar.xml · derivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-08-28 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the date of grant until the fourth anniversary of the date of grant (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 20:50 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000543 · edgar.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Issuer's Amended and Restated 2012 Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of Common Stock. The restricted stock units vest on August 28, 2019, provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on such vesting date. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:20 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0001209191-18-046028 · doc4.xml · derivative · entry 7 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock, par value $0.01 per share · 50,000 shares Expires 2025-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The option vested in four equal annual installments on each of January 1, 2016, 2017, 2018 and 2019. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:20 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-18-046028 · doc4.xml · derivative · entry 6 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 20,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: The option vested in four equal annual installments on each of January 1, 2015, 2016, 2017 and 2018. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:20 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-18-046028 · doc4.xml · derivative · entry 5 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 30,000 shares Expires 2023-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The option vested in four equal annual installments on each of November 18, 2014, 2015, 2016 and 2017. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:20 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 100,015 | $6.08 | $608,091.20 |
DisclosureSEC source: 0001209191-18-046028 · doc4.xml · nonDerivative · entry 4 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,286 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6). F7 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:20 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 37,500 | $5.56 | $208,500.00 |
DisclosureSEC source: 0001209191-18-046028 · doc4.xml · nonDerivative · entry 3 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 100,015 shares of common stock held by the Reporting Person. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:20 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 20,000 | $4.12 | $82,400.00 |
DisclosureSEC source: 0001209191-18-046028 · doc4.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 62,515 shares of common stock held by the Reporting Person. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:20 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 30,000 | $4.31 | $129,300.00 |
DisclosureSEC source: 0001209191-18-046028 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (e) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (continued in footnote 3 below) F3 · balance_after: (continuation of footnote 2 above) (f) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; (g) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (h) 42,515 shares of common stock held by the Reporting Person. Read SEC document |
| August 03, 2018 Filed Aug 13, 2018 20:10 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 5,170 | $5.70 | $29,469.00 |
DisclosureSEC source: 0001209191-18-046408 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,058 F1 · shares: The shares were disposed to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain restricted stock units previously granted to the Reporting Person on August 3, 2015. F2 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (e) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (f) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; and (g) 8,889 shares of common stock held by the Reporting Person. Read SEC document |
| July 27, 2018 Filed Jul 31, 2018 20:08 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-18-044542 · doc4.xml · derivative · entry 5 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.01 per share · 40,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The option vested in four equal annual installments on each of January 1, 2015, 2016, 2017 and 2018. Read SEC document |
| July 27, 2018 Filed Jul 31, 2018 20:08 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-18-044542 · doc4.xml · derivative · entry 4 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, par value $0.01 per share · 60,000 shares Expires 2023-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The option vested in four equal annual installments on each of November 18, 2014, 2015, 2016 and 2017. Read SEC document |
| July 27, 2018 Filed Jul 31, 2018 20:08 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 62,514 | $5.54 | $346,327.56 |
DisclosureSEC source: 0001209191-18-044542 · doc4.xml · nonDerivative · entry 3 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,801 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5). F6 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 12,515 shares of common stock held by the Reporting Person. Read SEC document |
| July 27, 2018 Filed Jul 31, 2018 20:08 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 20,000 | $4.12 | $82,400.00 |
DisclosureSEC source: 0001209191-18-044542 · doc4.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 75,029 shares of common stock held by the Reporting Person. Read SEC document |
| July 27, 2018 Filed Jul 31, 2018 20:08 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 30,000 | $4.31 | $129,300.00 |
DisclosureSEC source: 0001209191-18-044542 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (e) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (continued in footnote 3 below) F3 · balance_after: (continuation of footnote 2 above) (f) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; (g) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (h) 55,029 shares of common stock held by the Reporting Person. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 23:13 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 5,570 | $5.25 | $29,242.50 |
DisclosureSEC source: 0001209191-18-044102 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,315 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (e) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (continued in footnote 3 below) F3 · balance_after: (continuation of footnote 2 above) (f) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; (g) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (h) 25,029 shares of common stock held by the Reporting Person. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:54 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 1,465 | $5.25 | $7,691.25 |
DisclosureSEC source: 0001209191-18-043624 · doc4.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,885 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 30,599 shares of common stock held by the Reporting Person. Read SEC document |
| July 19, 2018 Filed Jul 23, 2018 20:54 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 1,100 | $5.25 | $5,775.00 |
DisclosureSEC source: 0001209191-18-043624 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,350 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (e) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (continued in footnote 3 below) F3 · balance_after: (continuation of footnote 2 above) (f) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; (g) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (h) 32,064 shares of common stock held by the Reporting Person. Read SEC document |
| July 13, 2018 Filed Jul 16, 2018 21:10 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 1,062 | $5.25 | $5,575.50 |
DisclosureSEC source: 0001209191-18-042657 · doc4.xml · nonDerivative · entry 3 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,450 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 33,164 shares of common stock held by the Reporting Person. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:10 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 5,828 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-18-042657 · doc4.xml · derivative · entry 4 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock, par value $0.01 per share · 45,828 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The option vested in four equal annual installments on each of January 1, 2015, 2016, 2017 and 2018. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:10 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 9,145 | $5.25 | $48,011.25 |
DisclosureSEC source: 0001209191-18-042657 · doc4.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,512 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 34,226 shares of common stock held by the Reporting Person. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:10 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 5,828 | $4.12 | $24,011.36 |
DisclosureSEC source: 0001209191-18-042657 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (e) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (continued in footnote 3 below) F3 · balance_after: (continuation of footnote 2 above) (f) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; (g) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (h) 43,371 shares of common stock held by the Reporting Person. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 54,172 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · derivative · entry 11 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,828 Underlying: Common Stock, par value $0.01 per share · 100,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · derivative.exercise_date: The option vested in four equal annual installments on each of January 1, 2015, 2016, 2017 and 2018. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionstock option (right to buy) · Derivative | 62,100 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · derivative · entry 10 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock, par value $0.01 per share · 122,100 shares Expires 2023-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · derivative.exercise_date: The option vested in four equal annual installments on each of November 18, 2014, 2015, 2016 and 2017. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 141,300 | $5.23 | $738,999.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · nonDerivative · entry 7 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,829 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11). F12 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 37,543 shares of common stock held by the Reporting Person. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 54,172 | $4.12 | $223,188.64 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · nonDerivative · entry 6 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 178,843 shares of common stock held by the Reporting Person. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 62,100 | $4.31 | $267,651.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · nonDerivative · entry 5 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 124,671 shares of common stock held by the Reporting Person. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 13,700 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · derivative · entry 9 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,100 Underlying: Common Stock, par value $0.01 per share · 135,800 shares Expires 2023-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · derivative.exercise_date: The option vested in four equal annual installments on each of November 18, 2014, 2015, 2016 and 2017. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 13,700 | $5.38 | $73,706.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · nonDerivative · entry 4 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,857 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.275 to $5.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7). F8 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 62,571 shares of common stock held by the Reporting Person. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 13,700 | $4.31 | $59,047.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · nonDerivative · entry 3 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 76,271 shares of common stock held by the Reporting Person. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 14,200 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · derivative · entry 8 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,800 Underlying: Common Stock, par value $0.01 per share · 150,000 shares Expires 2023-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · derivative.exercise_date: The option vested in four equal annual installments on each of November 18, 2014, 2015, 2016 and 2017. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 14,200 | $5.41 | $76,822.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,857 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.40 to $5.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F5 · balance_after: Includes the awards referenced in clauses (a) through (g) of footnotes (2) and (3) above plus 62,571 shares of common stock held by the Reporting Person. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 01:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 14,200 | $4.31 | $61,202.00 |
DisclosureSEC source: 0001209191-18-042413 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (e) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (continued in footnote 3 below) F3 · balance_after: (continuation of footnote 2 above) (f) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; (g) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (h) 76,771 shares of common stock held by the Reporting Person. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:08 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033771 · doc4.xml · nonDerivative · entry 2 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,857 F3 · shares: Represents a deferred stock award of 40,000 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in three equal annual installments on May 24, 2019, May 24, 2020 and May 24, 2021, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from May 24, 2018 to the earlier of (i) May 24, 2019 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F4 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; and (b) all awards and common stock held by the Reporting Person as described in footnote 2 above. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:08 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033771 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,857 F1 · shares: Represents a deferred stock award of 40,000 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022. F2 · balance_after: Includes (a) a deferred stock award of 40,000 restricted stock units which vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (b) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (c) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (d) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (e) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; (f) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (g) 62,571 shares of common stock held by the Reporting Person. Read SEC document |
| May 06, 2018 Filed May 8, 2018 20:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 26,081 | $5.00 | $130,405.00 |
DisclosureSEC source: 0001209191-18-028568 · doc4.xml · nonDerivative · entry 1 Gagnon Robert E. · CIK 0001504983 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,857 F1 · shares: The shares were disposed to satisfy the Reporting Person's tax withholding obligation in connection with deferred stock awards previously granted to the Reporting Person which vested on May 6, 2018. F2 · balance_after: Includes (a) a deferred stock award of 81,522 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (b) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (c) a deferred stock award of 44,326 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (d) a deferred stock award of 6,625 restricted stock units which shall vest in full on January 1, 2019; (e) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (f) 62,571 shares of common stock held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.